ZYME EBITDA
-$140.25MTTM · USD
Period ending:
ZYME FY EBITDAUSD
$142.49M-$206.09M
2014-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
ZYME ebitda history
Earnings before interest, taxes, depreciation, and amortization. The available annual fiscal periods series contains 12 observations from Dec 31, 2014 to Dec 31, 2025.
| Period ending | EBITDA (USD) |
|---|---|
| -68,644,000 | |
| -108,624,000 | |
| -120,702,000 | |
| 142,490,000 | |
| -206,089,000 | |
| -176,841,000 | |
| -143,097,000 | |
| -30,755,000 | |
| -6,083,000 | |
| -36,260,000 | |
| -18,624,000 | |
| -12,336,000 |
Compare ebitda
Other companies in Health Care. Each page shows its own reporting periods and currency.
- Guardant Health Inc (GH) ebitda
- Bridgebio Pharma Inc (BBIO) ebitda
- Brightspring Health Services Inc (BTSG) ebitda
- Madrigal Pharmaceuticals Inc (MDGL) ebitda
- Ensign Group Inc (ENSG) ebitda
- Glaukos Corp (GKOS) ebitda
- Vaxcyte Inc (PCVX) ebitda
- Krystal Biotech Inc (KRYS) ebitda
All ZYME financial metrics · ZYME stock overview · How to interpret financial metrics
